Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, as it looks to boost growth.
Source: cnbc.com
Eyebiotech Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eyebiotech Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eyebiotech Ltd Today - Breaking & Trending Today
Baystreet.ca - Merck to Buy EyeBio, Shares Climb
Merck (NYSE:MRK) on Wednesday agreed to acquire privately held biotech EyeBio for as much as $3 billion, the latest in a string of deals by the U.S. drugmaker to bolster its future growth. It agreed to pay $1.3 billion in cash and another $1.7 billion ...
Source: baystreet.ca
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034
/PRNewswire/ -- DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...
Source: prnewswire.com
According to Future Market Insights, the non-surgical segment by treatment type is predicted to acqu
In fiscal year 2023, the market for exophthalmos treatment is anticipated to be valued US$ 271.8 million, up from US$ 251.2 million in fiscal year 2022. The worldwide market is anticipated to increase steadily between 2023 and 2033, increasing its value to US$ 598 million by the end of that year.Graves’ illness is m...
Source: pharmiweb.com
Exophthalmos Treatment Market is projected to reach a size of US$ 598 Million by 2033
In fiscal year 2023, the market for exophthalmos treatment is anticipated to be valued US$ 271.8 million, up from US$ 251.2 million in fiscal year 2022. The worldwide market is anticipated to increase steadily between 2023 and 2033, increasing its value to US$ 598 million by the end of that year.Graves’ illness is m...
Source: pharmiweb.com